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Abstract
Background: No study has compared the associations of headache, anxiety, and depression at baseline with
muscle soreness or pain (MS/P) at baseline and at the two-year follow-up point among outpatients with major
depressive disorder (MDD). This study aimed to investigate the above issue.
Methods: This study enrolled 155 outpatients with MDD at baseline, and 131 attended a two-year follow-up
appointment. At baseline, migraine was diagnosed based on the International Classification of Headache Disorders,
2nd edition. MDD and anxiety disorders were diagnosed using the Structured Clinical Interview for DSM-IV-TR. The
visual analog scale was used to evaluate the intensities of headache and MS/P in the neck, shoulder, back, upper
limbs, and lower limbs. Depression and anxiety were evaluated using the Hospital Anxiety and Depression Scale.
Multiple linear regressions were used to compare the associations of these factors with MS/P.
Results: Compared with anxiety disorders, migraine was more strongly associated with MS/P in all areas at baseline
and in the upper and lower limbs at follow-up. Headache intensity at baseline was the factor most strongly associated
with MS/P in all areas at baseline and follow-up after controlling for depression and anxiety. Headache intensity at
baseline predicted MS/P at baseline and follow-up.
Conclusions: Migraine and headache intensity are important factors related to MS/P at baseline and follow-up among
patients with MDD. Integrating depression and headache treatment might be indicated to improve MS/P.
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Background
Depression and muscle soreness or pain (MS/P) are
closely related and interact [1–3]. Chronic muscle pain
is frequently accompanied by symptoms of depression
[2]. Major depressive disorder (MDD) is common
among chronic pain patients with myofascial pain syn-
drome [4]. Co-occurrence of musculoskeletal pain and
depressive symptoms is strongly related to poor self-
rated physical work ability [3]. Among patients with de-
pression, muscle soreness is one of the factors that
independently predict a slower remission after control-
ling for the baseline severity of depression [5].
Headache, depression, and anxiety are closely related
and interact [6–8]. A strong bidirectional association be-
tween migraine and psychiatric disorders has been docu-
mented [8]. Migraine is common among patients with
MDD and bipolar disorders [9–11]. Migraine is related
to poorer recovery of health-related quality of life after
acute pharmacotherapy among patients with MDD [12].
MDD patients with migraine are associated with greater
severities of depression, anxiety, and somatic and pain
symptoms [9, 10, 13, 14]. Migraine is also associated
with an increased frequency of suicidal ideation and sui-
cide attempts in patients with MDD [8]. Migraine and
* Correspondence: sjwang@vghtpe.gov.tw
4Faculty of Medicine, National Yang-Ming University School of Medicine and
Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
5Department of Neurology, Taipei Veterans General Hospital, No. 201 Shi-Pai
Road, Section 2, Taipei 112, Taiwan
Full list of author information is available at the end of the article
The Journal of Headache
                           and Pain
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Hung et al. The Journal of Headache and Pain  (2016) 17:57 
DOI 10.1186/s10194-016-0648-3
other headaches in a general population are associated
with increased musculoskeletal symptoms [15].
Anxiety is associated with musculoskeletal symptoms
[1, 16]. Increased muscle tension is one criterion for
generalized anxiety disorder (GAD) [17]. Fifty percent of
workers with persistent musculoskeletal pain undergoing
work rehabilitation initially exhibited GAD symptoms
[18]. Anxiety and/or depression are factors related to
poor outcomes and disability related to musculoskeletal
pain [19, 20]. Anxiety, depression, and migraine were as-
sociated with pain in the back, neck, orofacial area, ab-
domen, joints, and chest, but the associations of
migraine with the six pains weakened substantially after
correction for the severity of anxiety and depression
[21]. Therefore, a considerable part of the comorbidity
of migraine and the six pains might be explained by de-
pression and anxiety [21].
As mentioned above, MS/P, migraine, depression, and
anxiety are closely related and interact. Investigation of
factors related to MS/P among patients with MDD is
important, because MS/P is related to a poor treatment
prognosis of depression and associated with occupa-
tional disability [3, 5, 20]. Although previous studies
have reported associations of migraine or other head-
aches with MS/P among patients with headaches or in a
general population [15, 22, 23], the associations of mi-
graine or headaches with MS/P among patients with
MDD have been neglected. No study has compared the
associations of migraine and anxiety disorders with
MS/P in addition to comparing the associations of
headache indices, depression, and anxiety with MS/P
at baseline and during long-term follow-up among
patients with MDD.
The aims of this study were to compare the associa-
tions of headaches, anxiety, and depression evaluated at
baseline with MS/P at baseline and at the two-year
follow-up point among patients with MDD.
We hypothesized that the association of headaches
with MS/P is not inferior to the associations of anxiety
and depression with MS/P after controlling for demo-
graphic and other variables.
Methods
Subjects
The study was approved by the Institutional Review
Board of Chang Gung Memorial Hospital, a medical
center in northern Taiwan. This project was conducted
in the psychiatric outpatient clinics of the same hospital
from September 2005 to August 2009. Written informed
consent, based on the guidelines regulated in the
Declaration of Helsinki, was obtained from all sub-
jects prior to their entrance into the study.
Study participants, aged 18–65 years, were recruited
from consecutive outpatients who met the DSM-IV- text
revision (TR) criteria for MDD [17] and were experien-
cing a current major depressive episode (MDE) and had
not taken antidepressants or other psychotropic drugs
within the previous four weeks. Three exclusion criteria
were established in order to prevent depression and pain
symptoms from being confounded by psychotic symp-
toms, substance abuse, or other medical conditions: 1)
psychotic symptoms, severe psychomotor retardation,
mental retardation, or catatonic features; 2) a history of
substance dependence or abuse without full remission in
the previous month; and 3) chronic medical diseases
such as diabetes mellitus, hypertension, severe neuro-
logical disorders, and other medical diseases, except for
headaches. The Structured Clinical Interview for DSM-
IV-TR Axis I Disorders was used to diagnose MDD and
anxiety disorders [24].
Assessment of headaches
A structured headache intake form was designed to meet
the operational criteria of the International Classifica-
tion of Headache Disorders, 2nd edition (ICHD-2) [25].
Questions regarding headache pattern, intensity, fre-
quency, location, duration, aggravation by physical activ-
ities, aura, nausea, vomiting, phonophobia, photophobia,
precipitating factors and medication usage for headache
were included. At baseline, subjects completed the struc-
tured headache intake form. An experienced headache
specialist, who was masked to the results of psychiatric
evaluations, interviewed all patients after they had com-
pleted the headache intake form and made diagnoses.
Patients who fulfilled the criteria of migraine without
aura and/or migraine with aura were categorized as the
“migraine” group, while the other subjects were catego-
rized as the “non-migraine” group.
The average headache intensity in the past week was
evaluated using a visual analog scale (VAS), with 0
representing “no pain” and 10 representing “pain as se-
vere as I can imagine”. The number of headache days in
the past week was recorded as the headache frequency.
The intensity and frequency were evaluated at baseline
and at two-year follow-up.
Assessment of anxiety disorders
One board-certified psychiatrist, who was masked to the
diagnoses of headaches and the psychometric results,
used the Structured Clinical Interview to diagnose the
following anxiety disorders: panic disorder, agoraphobia,
specific phobia, social phobia, obsessive–compulsive dis-
order, post-traumatic stress disorder, and GAD [24]. Pa-
tients with any one of the anxiety disorders in a current
episode or partial remission were categorized as the
“anxiety disorders” group, while the others were classi-
fied as the “non-anxiety disorders” group.
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Assessment of muscle soreness or pain, depression,
and anxiety
The average MS/P in the past week was evaluated by
using a VAS, with 0 representing “no pain” and 10 repre-
senting “pain as severe as I can imagine”. MS/P in five
areas was evaluated, including the neck, shoulder, back,
upper limbs, and lower limbs.
The severities of depression and anxiety were evalu-
ated by the Hospital Anxiety and Depression Scale
(HADS). The HADS includes 7 items for the anxiety
subscale (HADS-A) and 7 for the depression subscale
(HADS-D), with the scores for each subscale ranging
from 0 to 21 [26, 27]. The HADS was used because it
does not include any somatic or pain symptoms, which
might be related to MS/P. The HADS and MS/P were
measured at baseline and follow-up.
Procedures
After enrollment, subjects were treated for four weeks
with venlafaxine extended-release, one 75 mg capsule
per day, and zolpidem. After the four-week treatment,
these patients were treated as general psychiatric outpa-
tients without controlling their pharmacotherapy. In the
following two years, some patients continued pharmaco-
therapy and others dropped out. Two years later, the
subjects were followed-up. Subjects with pharmacother-
apy in the index follow-up month were categorized into
the treated group and those without were categorized
into the not treated group.
Statistical methods
All statistical analyses were performed using SPSS for
Windows 12.0 (SPSS Inc., Chicago, IL, USA). The inde-
pendent t test, the Mann-Whitney U test, the paired t
test, Pearson’s correlation, Spearman’s correlation and
the Chi-square test were used as appropriate.
Two models of multiple linear regressions with for-
ward selection were used to compare the associations of
these independent variables with MS/P in the five areas
at baseline and two-year follow-up after controlling for
other factors. The first regression model compared the
associations of two categorical variables (migraine and
anxiety disorders) diagnosed at baseline with MS/P in
the five areas at baseline and at the two-year follow-up
point. The second model compared the associations of
four continuous variables (headache intensity, headache
frequency, HADS-D score and HADS-A score) evalu-
ated at baseline with MS/P in the five areas at baseline
and at the two-year follow-up point. In the first and
second models, the dependent variables were MS/P
(VAS scores) in the five areas at baseline and follow-up.
In the first model, the independent variables included
five demographic variables (gender, age, marital sta-
tus, educational years, and employment status), with
pharmacotherapy or not at follow-up, with migraine
or not at baseline, and with anxiety disorders or not
at baseline. In the second model, the independent
variables included five demographic variables, the
four continuous variables (headache intensity, head-
ache frequency, HADS-D score and HADS-A score)
at baseline, and whether or not pharmacotherapy is
being used at follow-up.
A two-tailed P value <0.05 was considered statistically
significant. In the comparison of MS/P in the five areas
between groups, Bonferroni correction was used and a




At baseline, 155 patients were enrolled (Table 1). At the
two-year follow-up, 131 patients agreed to participate in
the follow-up, 11 patients refused to participate, and 13
patients were unable to be contacted by phone and mail.
There were no significant differences in the five demo-
graphic variables, the percentages of migraine and anx-
iety comorbidities, the HADS scores, or the headache
indices between the patients who were followed-up and
those who were not followed-up.
At the two-year follow-up, of 30 patients in the treated
group, 18 (60.0 %) and 12 were treated with venlafaxine
(mean dosage of 102.1 ± 49.5 mg per day) and other an-
tidepressants, respectively. Benzodiazepine or other hyp-
notics were used in 19 (63.3 %) subjects.
Table 1 Demographic variables and comorbidities among
patients with major depressive disorder
Baseline Two years
Case number 155 131
Age (years) 30.3 ± 8.0 32.5 ± 8.3
Educational years 13.4 ± 2.5 13.5 ± 2.5
Female (%) 68.4 66.4
In employment (%) 59.4 58.8
Married (%) 38.7 40.5
With pharmacotherapy (%) – 22.9
With migraine (%) 47.1 46.6
With anxiety disorders (%) 45.2 45.8
HADS-D scoresa 14.4 ± 3.4 7.1 ± 5.3
HADS-A scoresa 14.8 ± 3.4 8.7 ± 4.6
Headache intensityb 4.2 ± 3.1 2.1 ± 2.6
Headache frequencyc 3.4 ± 2.6 2.2 ± 2.5
HADS-D the depression subscale of the Hospital Anxiety and Depression Scale
(HADS), HADS-A the anxiety subscale of the HADS
a50.3 and 56.1 % of the subjects had severe depression and anxiety at
baseline, respectively, with HADS-D and HADS-A scores ranging from 15 to 21
bThe average headache intensity, measured using a visual analog scale, in the
past week
cThe headache days in the past week
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Headache and psychiatric diagnoses
Among the 155 subjects at baseline, 73 (47.1 %) had
migraine, including 16 subjects with chronic migraine, 2
with chronic migraine and medication overuse headache,
49 with episodic migraine without aura, and 6 with
episodic migraine both with and without aura. The other
82 participants included 27 with probable migraine
without aura, 1 with chronic tension-type headache
(TTH), 30 with episodic TTH, 6 with probable episodic
TTH, 9 with headache unspecified, and 9 without any
headaches.
At baseline, 70 (45.2 %) patients had at least one anx-
iety disorder, including 15 (9.7 %) with panic disorder
and/or agoraphobia, 38 (24.5 %) with social phobia, 28
(18.1 %) with specific phobia, 18 (11.6 %) with post-
traumatic stress disorder, 10 (6.5 %) with obsessive-
compulsive disorder, and 11 (7.1 %) with GAD.
MDD subjects with migraine had a higher risk of co-
morbidity with any one of the anxiety disorders (63.4 %
vs. 28.0 %, odds ratio = 4.64, P <0.001) as compared with
MDD subjects without migraine.
Differences in the severities of MS/P between groups
Table 2 shows the severities of MS/P at baseline and
follow-up. For the full sample at baseline and follow-up,
there was a trend that MS/P in the shoulder was of the
greatest severity, followed by the neck, back, and limbs.
At baseline, the patients with migraine had significantly
(post-Bonferroni correction; P <0.01) greater severities
of MS/P in the five areas as compared with the patients
without migraine. Compared with patients without anx-
iety disorders, patients with anxiety disorders also had
significantly (P <0.01) higher pain intensities in the five
areas, except for neck soreness or pain.
At the two-year follow-up point, differences in MS/P
in all areas post-correction were not significant between
patients with and without migraine or between patients
with and without anxiety disorders, both in the treated
and not treated groups.
At the two-year follow-up point, the severities of MS/
P in the five areas, HADS-A, HADS-D, and headache
indices had significantly (P <0.05) decreased both in the
treated and not treated groups compared with these var-
iables at baseline, except for the severities of MS/P in
the upper and lower limbs and two headache indices in
the treated group.
The correlations of MS/P with headache indices,
depression, and anxiety
Table 3 shows the correlations of MS/P at baseline and
follow-up with headache indices, depression, and anxiety
at baseline. At baseline, the correlations of MS/P in all
areas with headache intensity, headache frequency, and
HADS-A scores were significant. However, the correla-
tions of MS/P with the HADS-D scores were not signifi-
cant, except for MS/P in the shoulder.
At the two-year follow-up point, the headache inten-
sity at baseline was significantly correlated with MS/P in
all areas in the treated and not-treated group, except for
MS/P in the neck in the not-treated group and in the
Table 2 The intensities of muscle soreness/pain between groups among patients with major depressive disorder at baseline and
follow-upa
Time points Treatment Comorbidities at baselineb Number Neck Shoulder Back Upper limbs Lower limbs
Baseline Full sample 155 5.0 ± 3.5 5.1 ± 3.6 3.8 ± 3.6 2.6 ± 3.2 2.3 ± 3.0
No Tx Migraine Yes 73 6.4 ± 3.2** 6.8 ± 3.2** 5.1 ± 3.7** 3.5 ± 3.4** 3.3 ± 3.2**
No Tx Migraine No 82 3.7 ± 3.3 3.7 ± 3.3 2.6 ± 3.1 1.7 ± 2.8 1.4 ± 2.4
No Tx Anxiety Yes 70 5.7 ± 3.5* 6.1 ± 3.5** 4.6 ± 3.9** 3.4 ± 3.4** 3.1 ± 3.3**
No Tx Anxiety No 85 4.4 ± 3.5 4.3 ± 3.5 3.1 ± 3.2 1.9 ± 2.9 1.7 ± 2.6
Two years – Full sample 131 3.0 ± 3.2 3.3 ± 3.1 2.0 ± 2.8 1.3 ± 2.3 1.5 ± 2.3
No Tx Migraine Yes 43 3.2 ± 3.6 3.9 ± 3.5 2.6 ± 3.3 1.9 ± 3.0* 2.0 ± 2.8*
No Tx Migraine No 58 2.8 ± 3.0 2.8 ± 2.8 1.8 ± 2.6 0.8 ± 1.4 1.1 ± 1.6
No Tx Anxiety Yes 45 3.4 ± 3.5 4.0 ± 3.4* 2.7 ± 3.3 1.9 ± 3.0* 2.0 ± 2.8*
No Tx Anxiety No 56 2.7 ± 3.0 2.7 ± 2.8 1.7 ± 2.5 0.7 ± 1.4 1.0 ± 1.6
Tx Migraine Yes 17 3.7 ± 2.8* 4.3 ± 2.9 2.2 ± 2.4 1.7 ± 2.6 2.1 ± 2.9
Tx Migraine No 13 1.5 ± 3.0 2.0 ± 3.1 1.2 ± 2.5 1.1 ± 1.8 1.2 ± 2.3
Tx Anxiety Yes 16 3.7 ± 3.2 4.0 ± 3.3 1.9 ± 2.7 1.3 ± 2.0 1.9 ± 2.7
Tx Anxiety No 14 1.7 ± 2.6 2.5 ± 3.0 1.7 ± 2.2 1.5 ± 2.7 1.5 ± 2.6
Tx accepted pharmacotherapy in the index follow-up month
aThe independent t test and the Mann-Whitney U test were used where appropriate
bAnxiety comorbidities represented patients with at least one of following anxiety disorders: panic disorder, agoraphobia, social phobia, specific phobia, post-traumatic
stress disorder, obsessive–compulsive disorder, and generalized anxiety disorder
*P < 0.05; **P < 0.01
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upper limbs in the treated group. Headache frequency at
baseline was significantly correlated with MS/P in the
shoulder in the not-treated group and MS/P in the neck
and lower limbs in the treated group. The correlations
of HADS-D and HADS-A scores with MS/P in all areas
were not significant in both groups, except for the
correlation of HADS-A with MS/P in the lower limbs in
the not-treated group.
Comorbidities independently associated with MS/P
In the first regression model (Table 4), migraine at base-
line was an independent factor related to MS/P in the all
areas at baseline after controlling for demographic
variables. At the two-year follow-up point, migraine at
baseline was also an independent factor related to MS/P
in the upper and lower limbs. A trend was noted that
the association of migraine with MS/P had decreased at
the two-year follow-up point. Anxiety disorder at base-
line was an independent factor related to MS/P in the
shoulder at the two-year follow-up.
Headache, depression, and anxiety independently
associated with MS/P
In the second regression model (Table 5), headache in-
tensity was the most important factor (with the greatest
R square change) related to MS/P in all areas at baseline
and follow-up after controlling for other factors.
Headache frequency did not enter these regressions.
Anxiety (HADS-A score) was a factor independently
associated with MS/P in three areas at baseline. How-
ever, anxiety was not a significant factor related to MS/P
in all areas at follow-up. Depression (HADS-D score)
was not a significant factor related to MS/P in all areas
at baseline and follow-up.
Discussion
Migraine at baseline was an independent factor related
to MS/P after controlling for other factors. The associ-
ation of migraine with MS/P was not limited to baseline
measurements, but persisted to the two-year follow-up
point in the upper and lower limbs. Previous studies
have reported that migraine is associated with increased
musculoskeletal symptoms and increased self-reported
muscle tension [15, 23, 28]. This might result from the
fact that migraine is related to increased intracranial and
extracranial mechanical sensitivities and associated with
somatosensory amplification [29, 30]. Repeated migraine
attacks might cause central sensitization, which is re-
lated to allodynia, hyperalgesia and spontaneous pain
Table 3 The correlations of muscle soreness/pain at baseline and two-year follow-up with headache indices, depression, and anxiety
at baseline
Time points Treatment Number Neck Shoulder Back Upper limbs Lower limbs
Baseline No Tx 155 HI 0.46** 0.45** 0.36** 0.29** 0.37**
No Tx 155 HF 0.36** 0.36** 0.20* 0.16* 0.16*
No Tx 155 HADS-D 0.12 0.17* 0.12 0.01 0.08
No Tx 155 HASD-A 0.26** 0.32** 0.33** 0.17* 0.19*
Two years No Tx 101 HI 0.13 0.31** 0.21* 0.26** 0.27**
No Tx 101 HF 0.02 0.21* 0.12 0.15 0.14
No Tx 101 HADS-D −0.02 −0.03 −0.04 −0.02 −0.05
No Tx 101 HASD-A 0.01 0.07 0.06 0.11 0.21*
Tx 30 HI 0.56** 0.41* 0.45* 0.32 0.39*
Tx 30 HF 0.42* 0.33 0.31 0.34 0.44*
Tx 30 HADS-D 0.08 0.03 −0.15 0.03 0.20
Tx 30 HASD-A 0.22 0.08 −0.02 −0.24 −0.07
HADS-D the depression subscale of the Hospital Anxiety and Depression Scale (HADS), HADS-A the anxiety subscale of the HADS, HI average headache intensity in
the past week, HF headache frequency measured by the headache days in the past week, Tx accepted pharmacotherapy in the index follow-up month
*P < 0.05; **P < 0.01
Table 4 Independent comorbidities associated with muscle
soreness/pain among patients with major depressive disordera,b
Areas Independent variable Beta R2 change t P
Neck(B) Migraine(B) 0.40 0.16 5.3 <0.01
Neck(2Y) No – – – –
Shoulder(B) Migraine(B) 0.43 0.19 6.0 <0.01
Shoulder(2Y) Anxiety disorders(B) 0.21 0.05 2.5 0.01
Back(B) Migraine(B) 0.35 0.12 4.6 <0.01
Back(2Y) No – – – –
Upper limbs(B) Migraine(B) 0.27 0.07 3.5 <0.01
Upper limbs(2Y) Migraine(B) 0.22 0.05 2.6 0.01
Lower limbs(B) Migraine(B) 0.32 0.10 4.2 <0.01
Lower limbs(2Y) Migraine(B) 0.21 0.04 2.4 0.02
aThe case numbers were 155 and 131 at baseline and two-year
follow-up, respectively
b“(B)” and “(2Y)” were used to represent the variable evaluated at baseline and
two-year follow-up, respectively
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[29, 31]. Therefore, MDD patients with migraine might
become more sensitive to other pains. One previous
study reported that the impact of migraine on physical
and pain symptoms might be greater than that of a
MDE among psychiatric outpatients [10]. The upper and
lower limbs were the areas continuously associated with
migraine at the two-year follow-up point. Previous stud-
ies have reported that limb pain is associated with mi-
graine and has been considered part of migrainous
syndrome [32–34]. In this study, migraine was more as-
sociated with MS/P in most areas than anxiety disorders.
Therefore, clinicians should not ignore migraine when
treating MS/P in patients with MDD.
Headache intensity at baseline was the factor most
strongly associated with MS/P at baseline and at the
two-year follow-up point. This demonstrated that the as-
sociation of headache intensity with MS/P was greater
than the associations of the severities of depression and
anxiety with MS/P. Previous studies have reported that
headache is related to musculoskeletal symptoms [15, 23].
Therefore, headache might be an important factor related
to central sensitization among patients with MDD. Our
results implied that headache intensity at baseline might
be an important marker related to MS/P among patients
with MDD. MDD patients with a greater intensity of
headache during a MDE might have greater severities of
MS/P at long-term follow-up. However, further evidence
may be needed in order to prove these hypotheses.
Three points were worthy of note. 1) One longitudinal
population-based cohort study found a bidirectional re-
lationship between headache and chronic musculoskel-
etal complaints [22]. Therefore, the pathophysiology of
headache and chronic musculoskeletal complaints might
overlap or be closely related. The study concluded that
chronic musculoskeletal complaints should be treated
not only to relieve them but also to prevent the develop-
ment of chronic daily headache, and vice versa [22]. This
conclusion hinted that treatment of migraine and
headache might be helpful to improve MS/P among
patients with MDD. 2) Depression, migraine, and fibro-
myalgia are often comorbid with each other and interact
[9, 10, 35–37]. Our study showed that migraine and
headache intensity were factors related to MS/P, an im-
portant characteristic of fibromyalgia [38], among pa-
tients with MDD. Our study provided further evidence
of correlations between depression, migraine, headache,
and fibromyalgia. 3) Our study demonstrated that head-
ache intensity was associated with MS/P to a greater ex-
tent than headache frequency. One previous study
reported that frequency of headache had a higher impact
than headache diagnosis on the association between
headache and musculoskeletal symptoms [15]. The im-
pact ranking of headache intensity, headache frequency,
and headache diagnoses associated with musculoskeletal
symptoms should be further investigated.
Several limitations or methodological issues should be
addressed. 1) In the clinical neutral study, subjects in the
treated and not treated groups were not divided by
randomization, but by patients’ decisions. This might
cause bias. Moreover, the division caused small sample
sizes, which hindered assessment of the statistical signifi-
cance. 2) Although pharmacotherapy was listed as an in-
dependent factor in the regression model, the content of
pharmacotherapy was not controlled at follow-up. Ana-
lysis of the impacts of different medications on MS/P
would be hindered by the small sample sizes. 3) The
headache intensity and frequency in the past week were
recalled by subjects. A more reliable method would be
to record headache parameters in a prospective head-
ache diary. 4) Our sample was collected from a medical
center. Expansion of the results of this study to the gen-
eral population should be performed cautiously. 5) This
study only focused on the association of migraine with
MS/P. Some patients with migraine might have comor-
bidity with TTH, which is also related to muscle tension.
The association of TTH with MS/P should be investi-
gated in future studies.
Conclusion
Compared with anxiety disorders, migraine was more
strongly associated with MS/P in all areas at baseline
and in the upper and lower limbs at the two-year follow-
Table 5 Independent factors associated with muscle soreness/
pain among patients with major depressive disordera,b
Areas Independent variable Beta R2 change t P
Neck(B) HI(B) 0.42 0.21 5.8 <0.01
HADS-A(B) 0.16 0.02 2.2 0.03
Neck(2Y) HI(B) 0.22 0.05 2.6 0.01
Shoulder(B) HI(B) 0.38 0.20 5.3 <0.01
HADS-A(B) 0.24 0.05 3.3 <0.01
gender(B) −0.17 0.03 −2.4 0.02
Shoulder(2Y) HI(B) 0.33 0.11 4.0 <0.01
Back(B) HI(B) 0.29 0.13 3.9 <0.01
HADS-A(B) 0.27 0.06 3.6 <0.01
gender(B) −0.15 0.02 −2.1 0.04
Back(2Y) HI(B) 0.25 0.06 3.0 <0.01
Upper limbs(B) HI(B) 0.29 0.09 3.8 <0.01
Upper limbs(2Y) HI(B) 0.27 0.08 3.2 <0.01
Lower limbs(B) HI(B) 0.37 0.14 4.9 <0.01
Lower limbs(2Y) HI(B) 0.30 0.09 3.5 <0.01
HADS-A the anxiety subscale of the Hospital Anxiety and Depression Scale,
HI = average headache intensity in the past week
aThe case numbers were 155 and 131 at baseline and two-year
follow-up, respectively
b“(B)” and “(2Y)” were used to represent the variable evaluated at baseline and
two-year follow-up, respectively
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up point among patients with MDD. Headache intensity
was the factor most strongly associated with MS/P in all
areas at baseline and follow-up after controlling for de-
pression, anxiety, and other factors. Headache intensity
evaluated at baseline had impacts on MS/P in all areas
not only at baseline, but also at the two-year follow-up
point. Migraine and headache intensity should not be
neglected in the treatment of MS/P in patients with
MDD. Simultaneously, treatment of depression and
headache might improve MS/P.
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